The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Celgene; Roche Pharma AG; Takeda
Travel, Accommodations, Expenses - Celgene; Roche Pharma AG; Takeda
Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy.
 
Suzanne Leijen
No Relationships to Disclose
 
Robin van Geel
No Relationships to Disclose
 
Gabe S. Sonke
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Novartis; Roche
 
Daphne de Jong
No Relationships to Disclose
 
Efraim H. Rosenberg
No Relationships to Disclose
 
Serena Marchetti
No Relationships to Disclose
 
Dick Pluim
No Relationships to Disclose
 
Erik D. van Werkhoven
No Relationships to Disclose
 
Shelonitda Rose
Employment - Merck
Stock and Other Ownership Interests - Merck
Expert Testimony - Merck
 
Mark Anthony Lee
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Jos H. Beijnen
No Relationships to Disclose
 
Jan H. M. Schellens
No Relationships to Disclose